Screening / Projects

3rd Health Programme (2014-2020)
Innovative Partnership for Action Against Cancer [iPAAC]
The general objective of the Joint Action – Innovative Partnership for Action Against Cancer (iPAAC JA) is to develop innovative approaches to advances in cancer control. The innovation that will be...
The general objective of the Joint Action – Innovative Partnership for Action Against Cancer (iPAAC JA) is to develop innovative approaches to advances in cancer control. The innovation that will be covered within the JA consists of further development of cancer prevention, comprehensive approaches to the use of genomics in cancer control, cancer information and registries, improvements and challenges in cancer care, mapping of innovative cancer treatments and governance of integrated cancer control, including a new analysis of National Cancer Control Plans. The development of innovative approaches to cancer control will be supplemented by a Roadmap on Implementation and Sustainability of Cancer Control Actions, which will support Member States in implementation of iPAAC and CANCON recommendations. The Roadmap will act as the central pillar of the JA, integrating the diverse topic areas, providing synergies between the topics, ensuring consideration of transversal issues for all topics and acting as the central comprehensive deliverable, integrating all the JA outputs. A variety of methods will be used to fulfil the general and specific objectives including pilot studies, working groups, expert panels, literature review and surveys. A governmental board will be in place to ensure that implementation and sustainability in national contexts are duly considered for each topic area. The proposal for the iPAAC JA proposes actions to address objective 1 of the 2017 annual work programme, that is promoting health, preventing diseases and fostering supportive environments for healthy lifestyles taking into account the ‘health in all policies’ principle. The work to be developed by the iPAAC JA is complementary to the outcomes of the EPAAC and CANCON Joint Actions, funded by the Second and Third Health Programmes and will build on their outputs, using the stakeholder networks as an optimal base for the development of innovative cancer control actions.
Start date: 01/04/2018 - End date: 31/03/2021

Call: Joint Actions 2017
Topic: Screening
3rd Health Programme (2014-2020)
FRAILTOOLS: A comprehensive validation of tools to screen and diagnose frailty in different clinical and social settings to provide instruments for integrated care in older adults [FRAILTOOLS]
There is a proved strong evidence of the usefulness of frailty as a predictive factor of relevant undesired outcomes in populations of older adults. Several studies have been published showing the uti...
There is a proved strong evidence of the usefulness of frailty as a predictive factor of relevant undesired outcomes in populations of older adults. Several studies have been published showing the utility of the concept in improving the prognostic accuracy and the prediction of different risks (hospitalization, surgical and non-surgical complications, length of stay, death, incident disability, etc) in emergency departments, cardiac surgery, surgical patients and in patients with cardiovascular disease. These studies have placed the focus in assessing population risk, while the validation process for these instruments as diagnostic or screening tools has been usually neglected.FRAILTOOLS aims to assess the usefulness as screening and diagnosis tools of some selected instruments to detect frailty in both clinical (Hospital and Primary Care) and social (nursing homes) settings, providing diagnostic algorithms clinically sound. Target groups are all of those older adults at risk for frailty (pre-frail) plus those that are frail and are at risk for developing disability. According to the published prevalence of these two conditions, the target population concerned by this project represent around 40-50% of older people older than 65 and 60-70% of people older than 75. Once determined the best tools of screening and diagnosis in different settings of care, we will reach conclusions for this people wherever the level of care they need and currently use. The benefit will expand to the Health Systems and Social Care as it will provide validated instruments that are necessary to provide an appropriate care for older adults by means of a comprehensive, continued, coordinated and integrated care.FRAILTOOLS consortium involves 6 of the most renowned partners in research on ageing and frailty from Spain, UK, Italy, France and Poland, plus the support of a number of highly relevant collaborating stakeholders fully committed with the project.
Start date: 01/05/2015 - End date: 31/12/2018

Call: Call for Proposals for Projects 2014
Topic: Screening
3rd Health Programme (2014-2020)
HepCare Europe: [HEPCARE EUROPE]
HCV infects and affects a population in the EU who do not access care. The arrival of new curative HCV drugs are a great opportunity for those resourced to attend services and adhere to treatment, bu...
HCV infects and affects a population in the EU who do not access care. The arrival of new curative HCV drugs are a great opportunity for those resourced to attend services and adhere to treatment, but this adherent population is the minority in the EU. If we aim to cure HCV in all risk groups we must take the treatment to the patient and vice-versa. The activities will support the development of national hepatitis strategies, screening and treatment guidelines, taking into account available treatment options. It will help to bridge primary, secondary care, and outreach in the community to facilitate access to and uptake of testing and treatment services particularly among key risk groups including drug users and homeless. It will also assess the potentially considerable economic impact of available treatment and testing strategies on health systems, which are under the responsibility of the EU Member States, with a view to inform decisions on balancing access to medicines with the financial sustainability of health systems. The HepCare project will contain six different components.HepCheck will aim at intensifying screening in the communityHepLink will link primary and secondary care HepEd will educate and up-skill healthcare professionals in the treatment of Hepatitis CHepFriend will provide a peer advocate support programme for patients to help treatment outcomesHepCost will assess the economic impact of the projectThe coordinator will have overall responsibility for disseminating the project impact and liaising with decision makers.The project will take place in 4 member states: Ireland, the UK, Spain and Romania.The HepCare Project will build on work undertaken by the European Commission, the European Centre for Disease Control and Prevention, and the European Monitoring Centre for Drugs and Drug Addiction with the aim of reducing morbidity and mortality related to hepatitis C and reducing the socioeconomic impact of hepatitis in the EU/EEA.
Start date: 01/05/2016 - End date: 31/10/2019

Call: Call for Proposals for Projects 2015
Topic: Screening